Telisotuzumab vedotin (brand name Emrelis) is a first-in-class antibody-drug conjugate (ADC) . It is specifically designed to treat advanced non-small cell lung cancer (NSCLC) that overexpresses the c-Met protein.
Telisotuzumab vedotin-tllv approved for adults with locally advanced or metastatic, non-squamous NSCLC with high c-Met protein overexpression (defined as ≥50% of tumor cells with strong 3+ staining) who have progressed on prior systemic therapy.
Telisotuzumab targets the c-Met receptor and is linked to a potent microtubule inhibitor (MMAE).
Once bound to a cancer cell, it is internalized, releasing the drug to kill the cell.
It is used for non-squamous, EGFR wild-type NSCLC with high c-Met overexpression after previous treatment.
Administered intravenously every 2 weeks.
LUMINOSITY study, showing a confirmed overall response rate (ORR) of approximately 35% in patients with high c-Met overexpression.
Common Side Effects: Include peripheral neuropathy, fatigue, decreased appetite, and peripheral edema.
VENTANA MET (SP44) RxDx Assay identifies eligible patients with the required level of c-Met overexpression.